News

CREATING A COMPREHENSIVE CASCADE: INCREASING ACCESS TO HIV AND HCV TREATMENT, CARE AND SUPPORT

CREATING A COMPREHENSIVE CASCADE: INCREASING ACCESS TO HIV AND HCV TREATMENT, CARE AND SUPPORT

On World AIDS Day 2017 CTAC is delighted to launch Creating a Comprehensive Cascade: Increasing Access to HIV and HCV Treatment, Care and Support, which reveals the injustice created by Canada’s disjointed approach to treatment access and suggests some possible solutions. It compares costs and access for three sample patients in jurisdictions across Canada illustrating the inequity…

ABBVIE’s MAVIRET™ approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes.

ABBVIE’s MAVIRET™ approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes.

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that Health Canada has granted approval for MAVIRET™ (glecaprevir/pibrentasvir tablets), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). read more